Ofatumumab is first self-administered, targeted B-cell treatment for relapsing MS. The first self-administered, targeted B-cell treatment for relapsing multiple sclerosis (MS) received FDA approval

Categories: Stem Cells therapy

NBScience

contract research organization

stem cell therapy